MyDocetaxel

Outcomes for patients receiving optimal exposure to imatinib are similar to other TKI

Sub-optimal responses and treatment failures with imatinib may be address4ed by exposure evaluation and dosing optimization.12,13

  • Help avoid sub-optimal therapeutic response

  • Help identify potential non-adherence to therapy

  • Help reduce toxicity in patients receiving too much drug, potentially improving the patient’s quality of life

 

Saladax Resources

5Fu FU FU FU

5Fu FU FU FU

Poster presented at Asco

 
stuff

stuff

stuff

 

Publications of Interest

 Population Pharmacokinetics/Pharmacodynamics of Docetaxel in Phase II Studies in Patients With Cancer

 Population Pharmacokinetics/Pharmacodynamics of Docetaxel in Phase II Studies in Patients With Cancer

The population pharmacokinetic/pharma- codynamic (PK/PD) approach was prospectively inte- grated intheclinicaldevelopment ofdocetaxel toassess the PK profile in a large population of patients and investigate systemic exposure as a prognostic factor for clinical outcome.

 
 Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel

 Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel

Pharmacokinetics/pharmacodynamics (PK/PD) mod- eling and simulation will be of strategic importance for pharmaceutical development in the next decades [1,2]. Specifically, these approaches contribute to study design optimization, better decision making during drug development and better use of the drug (more informative labeling).

 
Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly

Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly

To prospectively study the pharmacokinetics and toxicity profile of docetaxel in elderly patients with cancer.

 

 
 
Current Chemo Dosing Practices

Current Chemo Dosing Practices

 

Text For Button

 

Text For Button